Transfusion Reactions, HDFN, Donor/Product Decisions, and Safety Workflow
Key Takeaways
- The first action for a suspected transfusion reaction is to stop the transfusion, maintain IV access with normal saline, notify the clinical team and blood bank, and begin clerical and laboratory investigation.
- Reaction timing and symptoms drive the differential: acute hemolysis, septic reaction, TRALI, TACO, allergic reaction, febrile nonhemolytic reaction, and delayed hemolysis have different first-priority clues.
- HDFN is caused by maternal IgG crossing the placenta; anti-D, anti-c, and anti-K are high-yield severe causes, while ABO HDFN is often milder.
- Rh immune globulin prevents anti-D alloimmunization in an unsensitized Rh-negative pregnant patient when fetal or neonatal D-positive exposure is possible.
- ASCP notes that donor eligibility questions use regulations current as of June 2023, including the FDA shift to individual risk-based donor questions.
Suspected transfusion reaction: first actions
The MLT exam repeatedly tests the first safe action. If a patient develops fever, chills, back pain, dyspnea, hypotension, hemoglobinuria, urticaria with systemic symptoms, or other concerning signs during transfusion, the immediate answer is not to choose a final diagnosis. The first action is to stop the transfusion and protect the patient.
A standard reaction workflow is:
- Stop the transfusion immediately.
- Keep IV access open with normal saline using new tubing according to policy.
- Notify the provider and blood bank.
- Perform bedside clerical checks: patient, unit, tag, compatibility label, and records.
- Send the blood component, tubing, postreaction specimen, and required forms to the blood bank.
- Begin laboratory investigation, often including visual hemolysis check, repeat ABO/Rh as needed, DAT, repeat crossmatch if indicated, and urine or plasma hemoglobin testing by policy.
- If sepsis is possible, culture the patient and component and notify required safety channels.
The clerical check is not a formality. ABO-incompatible transfusion is often caused by identification failure, not by exotic serology.
Reaction patterns
Use timing, symptoms, and lab clues to choose the best differential.
| Reaction | Typical timing and clues | Blood bank concern |
|---|---|---|
| Acute hemolytic transfusion reaction | Minutes to hours; fever, chills, back or flank pain, hypotension, hemoglobinuria, DIC | ABO error or other incompatible red cell antibody; stop transfusion and investigate urgently |
| Febrile nonhemolytic reaction | Fever or chills without hemolysis evidence | Recipient cytokine or leukocyte antibody response; diagnosis of exclusion after hemolysis is ruled out |
| Mild allergic reaction | Urticaria or itching with stable vital signs | Plasma protein sensitivity; provider may treat and decide whether to restart |
| Anaphylactic reaction | Hypotension, bronchospasm, angioedema, shock | Severe plasma protein reaction, classically IgA-related in selected patients |
| TRALI | Acute hypoxemia and noncardiogenic pulmonary edema within 6 hours | Donor HLA or neutrophil antibodies and recipient inflammation are classic concepts |
| TACO | Dyspnea with volume overload, hypertension, elevated BNP, positive fluid balance | Too much volume or too rapid transfusion for patient tolerance |
| Septic transfusion reaction | High fever, rigors, hypotension, shock; platelets are a classic risk | Bacterial contamination; culture component and patient |
| Delayed hemolytic reaction | Days to weeks; falling hemoglobin, jaundice, positive DAT, new antibody | Anamnestic alloantibody, especially Kidd, Rh, Duffy, or Kell |
| TA-GVHD | Days to weeks; fever, rash, diarrhea, liver dysfunction, pancytopenia | Prevent with irradiated cellular components for at-risk recipients |
TRALI and TACO are a common exam pair. TRALI is acute lung injury without circulatory overload. TACO is volume overload, often with hypertension, elevated venous pressure, response to diuretics, and positive fluid balance. Both can present with respiratory distress, so the question's hemodynamic clues matter.
HDFN decision logic
Hemolytic disease of the fetus and newborn (HDFN) occurs when maternal IgG crosses the placenta and destroys fetal or neonatal red cells. IgM does not cross the placenta effectively, so IgG antibodies are the classic problem.
High-yield severe causes include anti-D, anti-c, and anti-K. Anti-K is especially important because it can suppress fetal red cell production as well as cause hemolysis. ABO HDFN can occur, often in group O mothers with A or B infants, but it is usually milder than severe Rh or Kell disease.
| HDFN step | MLT exam focus |
|---|---|
| Prenatal screen | Identify clinically significant maternal IgG antibodies |
| Newborn testing | Cord or neonatal ABO/Rh as required, DAT, bilirubin/hemoglobin correlation |
| Eluate | Identifies antibody coating neonatal red cells when DAT is positive |
| RhIG prevention | Give to unsensitized Rh-negative mothers when D-positive fetal exposure is possible |
| Fetomaternal hemorrhage testing | Screen and quantify bleed to determine RhIG dose when needed |
| Transfusion support | Use antigen-negative, compatible, often irradiated and CMV-reduced products by neonatal policy |
Rh immune globulin is passive anti-D. It prevents the mother's immune system from forming active anti-D after exposure to D-positive fetal red cells. It does not treat a mother who already has immune anti-D. Common exam triggers include routine antenatal prophylaxis around 28 weeks, postpartum prophylaxis if the infant is D positive or weak D positive, and additional dosing after sensitizing events such as trauma, amniocentesis, or miscarriage according to policy and gestational age.
Donor eligibility and product safety frame
The ASCP MLT content guideline specifically notes that blood banking donor eligibility questions are based on current regulations as of June 2023. That date matters because FDA recommendations moved U.S. blood donor screening toward individual risk-based questions rather than broad sex- or gender-based categories.
For exam purposes, donor eligibility is usually a first-pass accept, defer, or investigate decision. Do not memorize a local donor center script as if it were universal. Know the major risk concepts and the June 2023 framing.
| Donor issue | June 2023-era exam direction |
|---|---|
| History ever of a positive HIV test or ever taking medication to treat HIV infection | Permanent deferral |
| Oral PrEP or PEP to prevent HIV infection | Defer for 3 months from the most recent dose |
| Injectable PrEP or PEP to prevent HIV infection | Defer for 2 years from the most recent injection |
| New sexual partner plus anal sex in the past 3 months | Defer for 3 months from most recent sexual contact |
| More than one sexual partner plus anal sex in the past 3 months | Defer for 3 months from most recent sexual contact |
| Exchange of sex for money, drugs, or other payment | Defer for 3 months from the most recent event |
| Nonprescription injection drug use | Defer for 3 months from the most recent event |
| Sex with a person who has ever had a positive HIV test, or with a recent exchange-sex or injection-drug-use risk | Defer for 3 months from most recent sexual contact |
| Allogeneic transfusion or blood exposure such as needlestick or mucous membrane exposure | Defer for 3 months from the transfusion or exposure |
| Tattoo, ear piercing, or body piercing | Defer for 3 months unless the tattoo was state-regulated with sterile needles and non-reused ink, or piercing used single-use equipment |
| Syphilis or gonorrhea, or treatment for either | Defer for 3 months after completion of treatment |
| Donor has a mild vasovagal reaction during collection | Stop or manage collection per donor safety procedure and document adverse reaction |
Do not tell a donor to stop prescribed HIV prevention medication to donate. FDA donor materials emphasize that medication decisions belong with the donor's clinician, and donor safety and recipient safety come before inventory pressure.
Product decisions inside safety workflow
Product safety also includes what to do after collection and before transfusion: required testing, labeling, storage, quarantine when testing is incomplete or reactive, and traceability from donor to recipient. If a donor test later becomes reactive after a component was distributed, the high-yield workflow is quarantine available co-components, notify the transfusion service or consignee, investigate lookback requirements, and follow regulatory and institutional reporting procedures.
At the bedside, patient blood management is part of safety. The best product is not always more product. The exam may reward recognizing when transfusion is indicated, when a component is mismatched to the clinical problem, or when a special modification is needed. Washed components help recurrent severe allergic reactions. Irradiated cellular components prevent TA-GVHD in defined high-risk patients. Antigen-negative red cells prevent hemolysis in patients with known clinically significant alloantibodies.
A patient develops fever, chills, back pain, and hypotension 10 minutes after an RBC transfusion begins. What is the first action?
A transfused patient develops acute hypoxemia and bilateral pulmonary infiltrates within 4 hours. Blood pressure is low, fluid balance is not positive, and there is no evidence of circulatory overload. Which reaction is most likely?
Which statements fit HDFN and RhIG decision logic? Select all that apply.
Select all that apply